FDA Gives Ozempic Two Drug Safety–Related Label Changes
The US Food and Drug Administration made two drug safety–related changes to the label for Ozempic, the weight-loss formulation of the GLP-1 receptor agonist semaglutide.
Medscape Medical News
source https://www.medscape.com/viewarticle/996912?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/996912?src=rss
Comments
Post a Comment